Dr. Jennifer Van
Eyk'sground-breaking
research into the protein changes associated with
heart failure formed the basis for Cardiomics
Inc., a functional proteomics company focused
on the identification and characterization of
protein markers and targets in cardiovascular
disease. Through the assistance of PARTEQ Innovations,
and under the guidance of CEO Dr. Geoffrey Flynn,
Cardiomics continues to develop its technologies
for diagnostic and therapeutic approaches to ischemic
heart disease.
